Home DaoYuan Portfolio Company Huanxin Medical's OccluFar Fengyou Mini Receives Market Approval, Ushering in a New Era of 'Occlusion + Delivery' in Neurointervention

DaoYuan Portfolio Company Huanxin Medical's OccluFar Fengyou Mini Receives Market Approval, Ushering in a New Era of 'Occlusion + Delivery' in Neurointervention

Jan 13, 2026 17:01 CST Updated 17:01
CardioCycle

Innovative Medical Device Developer

Recently, OccluFar Mini Balloon Occlusion Microcatheter, developed by CardioCycle, an outstanding company invested in by Daoyuan, has been officially approved for marketing. The launch of OccluFar Mini not only signifies the further expansion of CardioCycle's product portfolio in the field of neurointervention but also heralds the arrival of a brand-new treatment concept in clinical practice: the era of neurointervention has arrived, shifting from "simple occlusion" to "coordinated occlusion and delivery."

Image


Subverting Tradition: The Revolution from "Single Occlusion" to "Two-in-One Platform"

Traditional nerve block balloons often play a single role of "temporary occlusion" during surgery, with limited functionality. The birth of CardioCycle Mini has completely broken this limitation. Its revolutionary dual-lumen design creates a truly integrated operating platform:


Occlusion Chamber: Achieving precise and compliant temporary blood flow control, creating a safe window for treatment.

Delivery Cavity: Specifically designed for a variety of therapeutic instruments, with excellent lumen compatibility.


"One-step, Synchronized Completion" – This innovative design concept enables interventional physicians to seamlessly transition from blood flow control to precise treatment in a single operation, significantly enhancing surgical efficiency and safety.

Image


Empowering Three Major Clinical Scenarios, Providing Annual Solutions for Complex Treatments


Focusing on Three Major Scenarios, Mini Balloon Empowers Complex Neurointerventions

Image


1. Arteriovenous Malformation Embolization Treatment: The "Guardian" of Coil Therapy

The Fengyou Mini can directly deliver coils with the assistance of a balloon, achieving "precise filling under occlusion protection." In complex cases such as wide-necked aneurysms, this integrated operation effectively prevents coil prolapse into the parent artery, significantly enhancing the density and stability of embolization while simplifying the traditionally complex process requiring multiple catheter exchanges.

Image


2. Arteriovenous Fistula Embolization Treatment: The "Safety Guardian" of Onyx Injection

During the injection of liquid embolic agents such as Onyx, the blood flow control function at the tip of the balloon is crucial. The SealTravel Mini allows for controlled injection under precise occlusion, significantly reducing the risk of embolic agent reflux and promoting its penetration into the core of the lesion. Technical validation by CardioCycle shows that this catheter system is fully compatible with the delivery requirements of liquid embolic agents like Onyx.

Image


3. Dense Mesh Stent Implantation: The "Optimization Master" for Postoperative Wall Apposition

Fengyou Mini, with its soft balloon, performs precise "massaging" of the dense mesh, promoting better adherence of the dense mesh stent to the vessel wall, optimizing blood flow direction, and creating a more ideal anatomical environment for the long-term healing of aneurysms.

Image



The Most Comprehensive Model Matrix: Providing "Tailor-Made" Solutions for Clinical Use

The launch of Fengyou Mini is not an isolated product release, but a crucial part of the comprehensive, systematic solution matrix that CardioCycle has meticulously developed in the field of neurointervention.


Full Specification Coverage: Outer diameters ranging from 1.7F to 2.1F, with four length specifications—110 cm, 130 cm, 135 cm, and 150 cm—offering tailored solutions for clinical use.


Image




About Daoyuan Capital

DaoYuan Capital is a leading private equity investment institution focused on the healthcare sector, dedicated to helping outstanding healthcare companies grow rapidly by leveraging capital and industry resources, providing better medical products and services to society, and enhancing human health.


Currently, Daoyuan Capital manages 20 RMB funds and 4 USD funds, with a total of 92 outstanding projects invested, including 16 IPO projects (one of which has obtained the CSRC registration approval). These include Priveye (301239), Jinxin Fertility (HK.1951), Sinomed (688108), Innovax (688253), Tinavi Medical Technologies (688277), Viva Biotech (HK.1873), Anbiping (688393), and Anges (688581), among others. In the next three years, more than 10 invested companies are expected to enter the IPO process.


Image